For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenue-Development Fee And Royalty | 0 | - | ||
| Total revenue | 0 | - | ||
| Research and development | 171,653 | 162,790 | ||
| General and administrative | 47,909 | 45,776 | ||
| Acquired in-process research and development | 0 | - | ||
| Gain on sale of in-process research and development asset | 10,000 | - | ||
| Total operating expenses | 209,562 | 208,566 | ||
| Loss from operations | -209,562 | -208,566 | ||
| Interest income | 24,885 | 21,312 | ||
| Change in fair value of forward contract liability-Forward Contracts | 0 | - | ||
| Other income (expense), net | 29,459 | -20,713 | ||
| Total other income (expense) | 54,344 | 599 | ||
| Loss before income tax expense | -155,218 | -207,967 | ||
| Income tax benefit (expense) | -15 | 51 | ||
| Net loss | -155,203 | -208,018 | ||
| Basic EPS | -79.02 | -127.21 | ||
| Diluted EPS | -79.02 | -127.21 | ||
| Basic Average Shares | 346,045 | 374,387 | ||
| Diluted Average Shares | 346,045 | 374,387 | ||
Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. (SYRE)